Breast Cancer– tag –
-
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 7)
Episode 7 | A Life-Course Prevention Playbook: Think in Life Events, Not Just Age—When to Seek Care, Screening Principles, and a Practical Summary Across this series, we placed breast, ovarian, and endometrial cancer risk on the same lif... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 2
Episode 2 | Breast Cancer Across Life Stages: Reading Risk Calmly with “Relative vs Absolute” Breast cancer is one of the most information-heavy topics in women’s health. Because it appears frequently in news and social media, it is also... -
How Respiratory Viral Infections May Alter Metastatic Risk in Breast Cancer: Latest Evidence and Practical Guidance
Even after successful primary treatment, disseminated cancer cells (DCCs) can persist in a dormant state for years and later “awaken,” leading to overt metastasis. Recent studies suggest that respiratory viral infections—such as influenz... -
Catchup News: HER2 ADC Special Report Part 2｜IP Strategies, Global Competition, and the Road Ahead
In Part 1 of our feature, we explored Enhertu’s groundbreaking pharmacological profile and its role in launching the second ADC boom. In this concluding part, we shift focus to intellectual property strategies, patent lifespans, and the ... -
Catchup News: HER2 ADC Special Report Part 1｜The Rise of Enhertu and Pharmacological Differentiation Driving the Second ADC Boom
Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Among them, HER2-targeted ADCs have undergone a dramatic transformation with the arrival of Daiichi Sankyo and AstraZeneca’s Enhertu, sparki...
1